The molecular profile of microglia under the influence of glioma

Wei Li1, Manuel B Graeber

  • 1Brain Tumor Research Laboratories, The Brain and Mind Research Institute, University of Sydney, 94 Mallett St, Camperdown, Sydney, NSW 2050, Australia.

Neuro-Oncology
|May 11, 2012
PubMed

Insights

Microglia play a complex role in glioblastoma, exhibiting both tumor-promoting and anti-tumor properties. Understanding their molecular profile is key to developing novel cell-based therapies for malignant glioma.

Area of Science:

  • Neuroscience
  • Immunology
  • Oncology

Background:

  • Microglia are key immune cells in the brain that significantly contribute to glioblastoma (GBM) tumor mass.
  • Existing research presents conflicting evidence regarding microglia's role in glioma, suggesting both tumor-supportive and anti-tumor functions.
  • Microglial behavior is influenced by glioma-derived molecules, cell surface receptors, and autocrine signaling.

Purpose of the Study:

  • To review the existing literature on microglia and glioma.
  • To provide a synopsis of the molecular profile of microglia in the context of glioma.
  • To establish a rational basis for the therapeutic use of microglia in malignant glioma.

Main Methods:

  • Literature review of experimental studies on microglia in glioma.
  • Analysis of molecular profiles of microglia under glioma influence.
  • Evaluation of microglia precursor cell potential for therapeutic applications.

Main Results:

  • Microglia exhibit multifaceted activities during glioma progression.
  • Microglia's dual role (tumor-promoting vs. anti-tumor) is influenced by complex molecular interactions.
  • Microglia precursors can cross the blood-brain barrier.

Conclusions:

  • Microglia present a complex therapeutic target in glioblastoma due to their multifaceted roles.
  • Targeting microglia's molecular profile offers potential for novel glioblastoma treatments.
  • The ability of microglia precursors to cross the blood-brain barrier makes them promising candidates for cell-based therapies in malignant glioma.

Related Concept Videos